FORTIS
Fortis Healthcare
Each stock's 10,000-path forecast, rendered as light.
Fortis Healthcare (FORTIS) Stock Analysis & Case Study
Is FORTIS a good buy? The data-driven verdict.
Fortis Healthcare (FORTIS) trades at ₹976,on the numbers it tread carefully, a Downstox Snapshot Score of 41/100.
On the numbers, Fortis Healthcare (FORTIS) tread carefully, a Downstox Snapshot Score of 41/100, weighing expensive at 69.6× earnings, ROE of 11.3%, a 85% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027–2031.
Last updated . Data snapshot for research, not investment advice.
FORTIS fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
Is FORTIS overvalued? FORTIS P/E vs its sector
FORTIS's P/E of 69.6× sits above the sector peer median of 15.9×, so on earnings it screens richer than peers, while its 0.10% dividend yield is below the peer median of 1.65%.
FORTIS share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 2.0y of FORTIS history (35%/yr drift, 30%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| FORTIS 2027 | ₹897 | ₹1,314 | ₹1,920 | +36% |
| FORTIS 2028 | ₹1,039 | ₹1,788 | ₹3,067 | +86% |
| FORTIS 2029 | ₹1,252 | ₹2,437 | ₹4,724 | +153% |
| FORTIS 2030 | ₹1,530 | ₹3,336 | ₹7,151 | +246% |
| FORTIS 2031 | ₹1,886 | ₹4,475 | ₹10,542 | +365% |
Median (P50) is the central estimate; the P10–P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability FORTIS goes up, or doubles?
The bull case for FORTIS
- A 10,000-path probability model puts a 85% chance the price is higher in a year, with a median target of ₹1,314 (+36%).
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹4,724.
The bear case & risks
- A rich 69.6× P/E leaves a thin margin of safety if growth slows.
- Return on equity is a soft 11.3%, capital efficiency trails higher-quality peers.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹1,252.
FORTIS volatility & expected range, how bumpy is the ride?
Over the last 2.0 years FORTIS compounded at 35%/year with annualized volatility of 30%. That volatility implies a 1-year 80% range of ₹897–₹1,920, the honest backbone behind any single price target.
FORTIS price forecast, the full 60-month probability fan
FORTIS price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds FORTIS hits common targets within the simulated horizon?
Full multi-horizon detail on the FORTIS price target & forecast page.
FORTIS Piotroski F-Score: 4/9, how financially strong is it?
The Piotroski F-Score grades financial strength on nine profitability, leverage and efficiency checks. FORTIS scores 4/9,mixed financial health.
FORTIS MTF margin & leverage, Upstox, Zerodha, Groww, Dhan
Margin Trading Facility lets you buy FORTIS with part of the capital. Lower margin % = higher leverage. Rates compared across brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| Upstox | 28.7% | 3.5× |
| Zerodha | 24.5% | 4.1× |
| DhanCHEAPEST | 23.0% | 4.3× |
Compare every broker on the FORTIS MTF page.
FORTIS vs peers,sector comparison
About Fortis Healthcare: sector, index & market-cap context
Fortis Healthcare (FORTIS) is a mid-cap NSE-listed company, and a constituent of the Nifty 100 index group, with a market capitalisation of ₹73,673 Cr. See more Nifty 100 stocks.
How the FORTIS Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Fortis Healthcare's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
FORTIS analysis, FAQs
Is Fortis Healthcare (FORTIS) a good buy?
On the numbers, Fortis Healthcare (FORTIS) tread carefully, a Downstox Snapshot Score of 41/100, weighing expensive at 69.6× earnings, ROE of 11.3%, a 85% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is FORTIS overvalued or undervalued?
FORTIS trades at 69.6× earnings versus a peer median of 15.9×, so it screens richer than its sector peers.
What is the FORTIS share price target for 2031?
FORTIS's probability-weighted 2031 median target is ₹4,475, with an 80% range of ₹1,886–₹10,542 (10,000-path Monte-Carlo).
What is the probability FORTIS doubles in 5 years?
The modelled probability of FORTIS reaching ₹1,926 (2×) within 5 years is 89%.
What is the bull case for FORTIS?
A 10,000-path probability model puts a 85% chance the price is higher in a year, with a median target of ₹1,314 (+36%).
What are the risks in FORTIS?
A rich 69.6× P/E leaves a thin margin of safety if growth slows. Return on equity is a soft 11.3%, capital efficiency trails higher-quality peers.